Education

PharmD and PhD Medicinal Chemistry, University of California San Francisco

Research Interests

• cost-effectiveness modeling
• clinical, economic, and policy implications of pharmacogenomic-based drug therapies
• managed care decision-making

Courses Taught

• Pharm 436: Pharmacoeconomics, Genetics & Healthcare
• Pharm 534: Economic Evaluation in Health & Medicine
• Pharm 535/Hserv 584: Evaluating Cost & Outcomes in Health & Medicine
• Pharm 597: Graduate Seminar

Experience

Dr. Veenstra is an Associate Professor in the Pharmaceutical Outcomes Research and Policy Program in the Department of Pharmacy, and a member of the Institute for Public Health Genetics at the University of Washington.

He graduated from the University of California San Francisco, with doctoral degrees in clinical pharmacy and computational chemistry. He conducted his postdoctoral training in outcomes research with the University of Washington, including a one-year externship with Roche Global Pharmacoeconomics. Dr. Veenstra’s primary research interests are the clinical, economic, and policy implications of pharmacogenomic-based drug therapies. His major research projects include association studies of genetic variants with the outcomes of warfarin treatment, and cost effectiveness studies of genetic tests for warfarin, breast cancer, and lung cancer therapies.

Dr. Veenstra’s other major research interest is the development of disease simulation models for chronic diseases, particularly hepatitis B. He has worked extensively with the Academy of Managed Care Pharmacy to develop guidelines and train decision makers in the practical application of cost-effectiveness models. Dr. Veenstra is an author on over 60 scientific publications, including the journals JAMA, NEJM, and Science. Dr. Veenstra's methodological expertise is in cost-effectiveness modeling, including decision analysis, Markov modeling, and Monte Carlo simulation. Dr. Veenstra also has significant experience in developing disease simulation and cost-effectiveness models for chronic diseases, particularly hepatitis B.

As part of an ongoing series of Academy of Managed Care Pharmacy (AMCP) educational programs, Dr. Veenstra has worked extensively with formulary managers to assist them in evaluating cost-effectiveness models submitted by manufacturers to health care plans.

Activities

Dr. Veenstra is a member of the Institute for Public Health Genetics at UW, the International Society for Pharmacoeconomics and Outcomes Research, and the International Health Economics Association. Dr. Veenstra is a past recipient of the PhRMA Foundation Career Development Award in Pharmacoeconomics.

Publications

1. Veenstra DL, Sullivan SD, et al. The cost effectiveness of pegylated alpha-interferon versus lamivudine in HBeAg positive chronic hepatitis B in the UK, Eur J Gastro, in press.

2. Ramsey SD, Veenstra DL, Garrison LP Jr, Carlson R, Billings P, Carlson J, Sullivan SD. Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests. Am J Manag Care. 2006 Apr;12(4):197-202.

3. Oestreicher N, Ramsey SD, McCune JS, Linden HM, Veenstra DL. The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma. Cancer 2005;104:2054-62.

4. Meckley L, Veenstra DL. Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: A cost-effectiveness analysis. Pharmacogenet Genomics 2006;16:139-47.

5. Carlson J, Henrikson NB, Veenstra DL,Ramsey SD. Economic analyses of human genetics services: A systematic review, Genet Medicine 2005;8:519-23.

6. Veenstra DL, You JH, Rieder MJ, Farin FM, Wilkerson HW, Blough DK, Cheng G, Rettie AE. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics. 2005;15:687-91.

7. Oestreicher N, Ramsey SD, Linden HM, McCune JS, van't Veer LJ, Burke W, Veenstra DL. Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genet Med. 2005 Jul-Aug;7(6):380-9.

8. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005 Jun 2;352(22):2285-93.

9. Lee TA, Veenstra DL, Iloeje UH, Sullivan SD. Cost of chronic hepatitis B infection in the United States. J Clin Gastroenterol. 2004;38(10 Suppl):S144-7. 10. Flowers CR, Veenstra D. The role of cost-effectiveness in the era of pharmacogenomics, Pharmacoeconomics 2004;22:481-493.

Associate Professor, Department of Pharmacy
veenstra@u.washington.edu